Cephalon To File Gabitril Generalized Anxiety Disorder Claim By Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cephalon plans to file an sNDA by mid-year for expanded use of its anti-seizure medication Gabitril to treat generalized anxiety disorder, pending the outcome of Phase III trials